Elsa Quintana
Revolution Medicines (United States)(US)
Research Areas
Cancer Immunotherapy and Biomarkers, Protein Kinase Regulation and GTPase Signaling, Pancreatic and Hepatic Oncology Research, HER2/EGFR in Cancer Research, Pancreatitis Pathology and Treatment
Most-Cited Works
- → Cancer interception with KRAS inhibitors in preclinical models of pancreatic ductal adenocarcinoma(2026)1 cited
- → Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-refractory KRAS G12C-mutant NSCLC for Immune Checkpoint Blockade(2026)
- → Abstract C019: RMC-5127, a RAS(ON) G12V-selective inhibitor, drives durable tumor regressions and increases T cell infiltration in KRAS G12V-driven syngeneic models(2026)